中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

54 records (took 0.086 seconds)

    Implantable therapy systems and methods
    42.
    发明授权
    Implantable therapy systems and methods 失效
    植入式治疗系统和方法

    公开(公告)号：US06179826B2

    公开(公告)日：2001-01-30

    申请号：US08741228

    申请日：1996-10-29

    Applicant: Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

    Inventor： Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

    IPC: A61M3100

    CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K9/0024 ,  A61K9/0085 ,  A61K35/55 ,  A61K2035/126 ,  A61M31/002 ,  A61M37/0069 ,  A61M39/0208 ,  A61M2210/0687 ,  A61M2210/0693 ,  B01J13/02 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  C12N11/04 ,  C12N2533/30 ,  A61M2230/005

    Abstract: Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a dibilatating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the proximal tip of the cannula (20b). Once the vehicle (40) is positioned near the proximal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).

    Abstract translation: 公开了植入式治疗系统，用于将局部和受控制的生物活性因子递送至患有二体化病症的受试者的脑，脊髓和其他靶区域。 本发明的方法涉及通常在患者体内暴露通常位于预定治疗部位（12）上方的插入部位。 具有定位在其中的闭塞器（30）或扩张器（104）的插管（20）插入插入位置，从而限定到治疗部位的通路。 在一些情况下，套管可以沿着预先位于治疗部位的导丝（102）的路径插入。 插管（20）优选为低摩擦聚合材料，例如聚四氟乙烯。 插管（20）通常具有用于接收封闭器（30）或扩张器（104）的开放近端，以及用于将神经活性因子递送至治疗部位（12）的开口远端，优选地为锥形末端。 然后将塞子（30）从插管（20）中取出，并且将包含生物活性物质的生物相容性系留载体（40）沿通道插入插管中。 推动器可以插入插管内，在车辆（40）后面，以将车辆的近端定位在套管（20b）的近端处。 一旦车辆（40）定位在套管（20）的近端附近，则套管从通道中移开，随后是推动器，使车辆（40）位于治疗部位（12）处。

    Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
    46.
    发明授权
    Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment 失效
    神经引导通道含有用细胞粘附肽片段衍生的生物人造三维水凝胶细胞外基质

    公开(公告)号：US5834029A

    公开(公告)日：1998-11-10

    申请号：US280646

    申请日：1994-07-20

    Applicant: Ravi Bellamkonda ,  John P. Ranieri ,  Patrick Aebischer

    Inventor： Ravi Bellamkonda ,  John P. Ranieri ,  Patrick Aebischer

    IPC: A61L27/00 ,  A61K38/00 ,  A61L27/20 ,  A61L27/22 ,  A61L27/38 ,  A61L27/52 ,  A61L31/00 ,  A61L31/04 ,  C07K7/06 ,  C07K7/08 ,  C07K14/78 ,  A61K35/30 ,  A61B17/08 ,  C12N5/00 ,  C12N11/10

    CPC classification number: A61L27/3839 ,  A61L27/20 ,  A61L27/227 ,  A61L27/52 ,  A61L31/005 ,  A61L31/047 ,  C07K14/78 ,  A61K38/00 ,  A61L2430/32 ,  Y10S530/812 ,  Y10S530/813

    Abstract: A bioartificial three-dimensional hydrogel extracellular matrix derivatized with a cell adhesive peptide fragment is provided for use in tissue regeneration or replacement. The choice of adhesive peptide fragment depends on the desired target cell type. Cartilage or tendon can be regenerated by implanting a matrix containing adhesive peptide fragments that favor chondrocyte invasion. The matrix can be pre-seeded with cells, and tissue can be reconstituted in vitro and then implanted. A cell-seeded matrix can be encapsulated in a semi-permeable membrane to form a bioartificial organ. An agarose hydrogel matrix having an agarose concentration of 0.5-1.25% (w/v) and an average gel pore radius between 120 nm and 290 nm is preferred. The peptide fragment preferably contains the sequence, ArgGlyAsp or TyrIleGlySerArg or IleLysValAlaVal, and is covalently immobilized to the matrix. A nerve guidance channel for use in regenerating severed nerve is prepared containing a tubular semi-permeable membrane having openings adapted to receive the ends of a severed nerve, and an inner lumen containing the matrix having an adhesive peptide fragment through which the nerve can regenerate.

    Abstract translation: 提供用细胞粘附肽片段衍生的生物人造三维水凝胶细胞外基质用于组织再生或替代。 粘合肽片段的选择取决于所需的靶细胞类型。 可以通过植入含有有利于软骨细胞侵袭的粘合肽片段的基质来再生软骨或肌腱。 基质可以用细胞预种子，组织可以在体外重建然后植入。 细胞接种的基质可以包封在半透膜中以形成生物人造器官。 琼脂糖水凝胶基质的琼脂糖浓度为0.5-1.25％（w / v），平均凝胶孔半径在120nm和290nm之间是优选的。 肽片段优选含有序列ArgGlyAsp或TyrIleGlySerArg或IleLysValAlaVal，并且共价固定在基质上。 制备用于再生切断的神经的神经引导通道，其包含具有适于接收切断的神经的末端的开口的管状半透膜，以及含有所述基质的内腔，所述内腔具有粘合肽片段，神经可通过所述粘合肽片段再生。

Patent Agency Ranking